UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private

Issuer Pursuant to Rule

13a-16 or 15d-16 under the

Securities Exchange Act

of 1934

For the month of ~~June~~July 2025

Commission File

Number: 001-38283

InflaRx N.V.

Winzerlaer Str. 2

07745 Jena,

Germany

(+49) 3641508180

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~OTHER~~EXPLANATORY ~~INFORMATION~~NOTE

~~Change~~On inJuly ~~Certifying~~11, ~~Accountant~~2025, InflaRx N.V. (the “Company”) issued a press release announcing that it had received a written notice (the “Notice”), dated as of July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until January 7, 2026, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until July 6, 2026, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing.

On June 26, 2025, InflaRx N.V. (the “Company”) executed an engagement letter with KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) to engage KPMG as its independent registered public accounting firm for the fiscal year ended December 31, 2025. In connection with this engagement, the Company ceased to engage EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft (“EY”) as its independent registered public accounting firm. EY had served as the Company’s independent registered public accounting firm since the fiscal year ended December 31, 2020. The ~~change~~Notice inhas ~~independent~~no ~~registered~~immediate ~~public~~effect ~~accounting firm follows the results of the Company’s Annual General Meeting of Shareholders held, in accordance with Dutch law,~~ on ~~April 24, 2025, where~~ the ~~Company’s~~listing ~~shareholders~~or ~~voted~~trading ~~to approve KPMG Accountants N.V. for the external audit~~ of the Company’s ~~statutory~~ordinary ~~annual accounts for the fiscal year ended December 31, 2025~~shares. The Company’s decision to make the change in auditor was not due to any disagreement with EY. EY did not resign or decline to stand for re-election and EY’s reports on the Company’s financial statements as of and for the year ended December 31, 2024 and as of and for the year ended December 31, 2023 and on internal control over financial reporting as of December 31, 2024 and as of December 31, 2023 were not qualified and did not contain an adverse or disclaimer of opinion.

The Company ~~will~~intends ~~provide~~to monitor the ~~additional~~bid ~~disclosures~~price inof ~~accordance~~its ~~with~~ordinary ~~Item~~shares ~~16F~~and ~~regarding~~consider ~~the~~available ~~predecessor~~options ~~auditor~~to inregain ~~its~~compliance ~~Form~~with ~~20-F for~~ the ~~fiscal~~Minimum ~~year~~Bid ~~ending~~Price ~~December 31, 2025~~Rule.

This report on Form 6-K (the “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of the Company and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

A copy of the press release is attached as Exhibit 99.1 to this Report. Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

FORWARD-LOOKING STATEMENTS

This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements,” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release, dated July 11, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 27, 2025
	INFLARX N.V.
	By:	/s/ Niels Riedemann
Date: July 14, 2025	By:	/s/ Niels Riedemann
		Niels Riedemann
	Name:	Niels Riedemann
		Chief Executive Officer
	Title:	Chief Executive Officer

Filing Compare · InflaRx N.V.